The Federal Open Market Committee’s (FOMC) October 31-November 1 monetary policy meeting brought the expected confirmation of Fed policy. The Fed left its funds target corridor at between 1.00 percent and 1.25 percent. The Fed Funds rate is expected to reach the 2-2.25 percent range by the end of next year, Commerzbank reported.
The statement released after the meeting signaled a more upbeat view of the economic situation. The Fed now sees the economy growing at a “solid” pace despite the impact of the severe storms. The September statement still spoke of “moderate” growth.
The US economy expanded at a rate of 3 percent in both Q2 and Q3. Based on this solid trend in economic activity, the Fed assumes that the labor market will continue to develop positively; the central bank specifically pointed to the further decline in the unemployment rate in September. However, inflation still hovers below the 2 percent mark. While the Fed sees no imminent change on this front, it still assumes that inflation will stabilize at 2 percent over the "medium-term".
The Fed said the risks to the economic outlook are thus "balanced" – a keyword for further policy normalization. All the signs point to a rate hike in December, at the next FOMC meeting, which markets have long expected. This hike would be the fifth rate move in this cycle.
FxWirePro launches Absolute Return Managed Program. For more details, visit http://www.fxwirepro.com/invest


South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility
MAS Holds Monetary Policy Steady as Strong Growth Raises Inflation Risks
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 



